Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma
Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
More information
Scope and Contents
Contents
To the Editor:
ECHELON-1, the trial reported by Connors et al. (Jan. 25 issue),
1
shows advancement in the treatment of Hodgkin’s lymphoma and introduces an effective regimen for patients who are unable to receive bleomycin. However, clinically meaningful outcomes in patients with curable cancers are reflected by overall survival, not modi...
Alternative Titles
Full title
Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2027593959
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2027593959
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc1802363
